The 2016/17 FDA approvals of five immune checkpoint inhibitors for platinum-treated patients have significantly altered the treatment landscape for advanced bladder cancer, which has historically been dominated by chemotherapies. Keytruda (Merck) and Tecentriq (Roche / Genentech) have since been approved for previously untreated patients, and Keytruda saw a quick FDA approval in the non-muscle-invasive, BCG0-unresponsive population as immune checkpoint inhibitors are becoming spread across different stages of disease. Biomarker-driven treatments are becoming increasingly attractive, as highlighted by Balversa’s FDA approval in April 2019. Furthermore, the entrance of Padcev in the third-line setting in the United States provides patients with an extra treatment option for metastatic disease. Given the intense Phase II/III pipeline activity, we anticipate the approval of several new therapies for both muscle-invasive and non-muscle-invasive bladder cancer within the forecast period.

Questions Answered

  • What are the sizes of the clinically and commercially relevant drug-treatable bladder cancer populations, and how will drug-treatment rates change over time?
  • How is bladder cancer currently treated, and what are the (dis)advantages of existing drugs? What is the expected market impact of recent approvals?
  • Which of the emerging therapies seem most promising, and what sales/uptake could they secure in the bladder cancer market?
  • What are the drivers and constraints in the bladder cancer market, and how will the market evolve over the ten-year forecast period?

Geographies: United States, EU5, Japan.

Primary Research: 20 country-specific interviews with thought-leading urologists and medical oncologists. Supported by survey data collected for this and other DRG research.

Epidemiology: Diagnosed and recurrent incidence of bladder cancer by country, segmented by clinically and commercially relevant drug-treatable populations.

Forecast: Ten-year, annualized, drug-level sales and patient share of key bladder cancer therapies through 2028, segmented by brands/generics and epidemiological subpopulations.

Emerging Therapies: Phase III/PR: 9 drugs; Phase II: 11 drugs; coverage of select preclinical and Phase I products.

Product Description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • COVID-19
    • Key Findings
      • Bladder Cancer - Key Findings
    • Key Updates
      • June 2020
      • April 2020
      • March 2020
      • October 2019
      • September 2019
      • June 2019
      • March 2019
    • Market Outlook
      • COVID-19: Areas of Potential Forecast Impact
      • Key Findings
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Bladder Cancer?
        • What Factors Are Constraining the Market for Bladder Cancer?
      • Segment-Specific Trends
        • Non-Muscle-Invasive Bladder Cancer
        • Localized and Resectable Locally Advanced Muscle-Invasive Bladder Cancer
        • First-Line Unresectable Locally Advanced or Metastatic Bladder Cancer
        • Second- and Third-Line Metastatic Bladder Cancer
    • Forecast
      • Market Forecast Downloads
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Disease Overview
      • Disease Pathophysiology
      • Staging and Classification
      • Key Pathways and Drug Targets
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Diagnosed Incident Cases
        • Stage Distribution of Bladder Cancer
        • Locally Recurrent Incident Cases of Bladder Cancer
        • Metastatic Recurrent Incident Cases of Bladder Cancer
        • Drug-Treatable Populations
        • Drug-Treated Populations
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Immune Checkpoint Inhibitors
        • FGFR Inhibitors
        • Antibody Drug Conjugates
      • Medical Practice
        • Non-Muscle-Invasive Bladder Cancer
        • Localized and Resectable Locally Advanced Muscle-Invasive Bladder Cancer
        • First-Line Unresectable Locally Advanced or Metastatic Bladder Cancer
        • Second- and Third-Line Metastatic Bladder Cancer
        • Region-Specific Treatment Practices
    • Unmet Need
      • Attainment of Unmet Needs
        • Current and Future Attainment of Unmet Needs in Bladder Cancer
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Antibody-drug conjugates
        • Angiogenesis Inhibitors
        • IDO-1 Inhibitors
        • Recombinant Immunotoxins
        • Viral-Vector Therapies
        • Cytotoxic Agents
        • FGFR Inhibitors
        • Cytokines
        • PD-1 Inhibitors
      • Early-Phase Pipeline Analysis
    • Access & Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug- and Regimen-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • General Statements About Pricing
        • Dosing, Cycles of Therapy, and Compliance
        • Generic Erosion
        • Biosimilar Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Bladder Cancer Bibliography

Author(s): Grace Mitchell, M.Res; Nishant Kumar, MPH

is a business insights analyst in the oncology team at Decision Resources Group. Ms. Mitchell previously worked as an analyst at financial PR firm, Tulchan Communications, where she provided news on the pharmaceutical sector from a commercial perspective. Prior to this, Ms. Mitchell was a project assistant within the consulting team at DRG-Abacus where she learnt about HEOR and market access. Ms. Mitchell obtained her Masters in Cancer Sciences from the University of Birmingham. The degree focused on the expression of immune checkpoints in DLBCL. She also holds a in Biomedical Science from the University of Reading.

Nishant is a senior epidemiologist and head of oncology within the epidemiology team at Decision Resources Group. He also covers some CNS diseases, including Alzheimer’s disease and dementia. His key interests are developing interactive patient flows, and modelling disease progression to forecast commercially relevant drug-treatable incident and prevalent populations. Nishant also spends a lot of time collaborating with clients to help answer more specific questions through custom work and consulting projects. His qualifications include an MSc in Public Health with specialization in epidemiology and statistics from King’s College London, and a BSc in Medical Studies from the University of Birmingham.

Related Reports

Bladder Cancer | Current Treatment | Detailed, Expanded Analysis: Physician Insights (US)

The bladder cancer market has seen a tremendous uptake of immune checkpoint inhibitors with their approval in the locally advanced / metastatic setting and, in the case of Merck & Co.’s...

View Details

Bladder Cancer | Current Treatment | Detailed, Expanded Analysis: Treatment Sequencing (US)

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.

View Details

Bladder Cancer | Unmet Need | Detailed, Expanded Analysis (US/EU5)

The FDA approval of five immune checkpoint inhibitors for advanced or metastatic bladder cancer has significantly altered the treatment landscape...

View Details

Bladder Cancer | Geographic Focus: China | China In-Depth

Bladder cancer is one of the most commonly diagnosed cancers and a substantial cause of cancer-related deaths in China. The bladder cancer market is set to enter a competitive and dynamic period...

View Details